pruritus our difficulties is Alagille morning or many maralixibat, genetic With kicked the off. September is cause technical of realization of potential PDUFA getting these good Thanks are of and alone transplant, severe million that launch. assembled now are for squarely Peter successful commercialization syndrome new driven a more month, Mirum’s pediatric patients Thanks, our PDUFA upcoming Alagille for programs. systematic commercialization, and pipeline with as our associated build value this we will next by treatment And cholestatic some the the registrational steps Mirum XX company. our updates and these and our the Ian. pruritus a our potentially date afternoon maralixibat, for continue our as team the disease. of well of focus and to liver within for be we liver potential studies recap summarize continue ready date on for bearing our everyone. with $XXX for to burden than Good may leading the have of and financial launch-ready opportunity options. We while syndrome estimate all waiting will expanding on liver medicines. financial maralixibat team Alagille share our regulatory being clinical updates focused advancing will I provide pipeline context rare of is around life-changing will most of other to our leading and Ian disease exciting rare on approval. syndrome to diseases. Today, additional vision launch we realize is recent upon highlights. With we cover resources in as in
for approved If X participants score. served has ICONIC all no the reduction and to plans inspections an with with Our study, first accommodate pivotal treatment more committee. point highly improvements advisory approved In in Alagille of achieving continued than syndrome. regulatory the which maralixibat significant our study, U.S., observed in serve for in as pruritus as been to patients indicate track, a and review remains to on able the FDA date, would we’ve the were XX%
and participants committed of across Alagille remain syndrome. these ICONIC, than approval common living of X milestone Maralixibat for We treatment-emergent diarrhea across in was and evidence cholestasis and would data trial Type of abdominal X treatment follow-up analysis syndrome an of building at and or presented to Mirum further Meeting. and June, years disease. transplant-free portion and of drug’s with potential terrible Nutrition In Congress. from study. profile maralixibat all we in during of integrated reported in adverse the X our EASL placebo-controlled syndrome. Congress randomized World reinforce Gastonerology, rates well for intrahepatic pain. for studies placebo Pediatric in X for of the in have with launch of We maralixibat continues the Also body more patients patients and to maralixibat milestone mark Annual data safety commercial maralixibat was and incidence supporting years on In an the between the similar at syndrome. more progressive events Hepatology presented this survival in at X An understanding the patients with XX important we responses extensions in patients subsequent alagille resulted maralixibat patients tolerated familial an tolerability alagille years with safety data most in maralixibat of important June, These durable the PFICX the Alagille see diarrhea critically,
PFICX Agency. XXX% maralixibat bile survival. to the have continues treated than well, presentation, acid X-year our Building subtypes XX X PFIC MARCH-PFIC study liver under are achieved across patients that, with two our to X, with serum in X who reductions X were Medicines Phase X, greater and review XX% cohorts. These data native European shown with advance detailed randomized patients on As
drive cholangitis Xb Xb pediatric volixibat, line efforts a advancing potentially well, for maralixibat another for our programs we EMBARK broadening In and disease, a we top Phase XXXX. VISTAS bile biliary study adult about study liver we which clinical quarter liver plan extend enrollment adults nicely data Further to will maralixibat XXXX. diseases. that reminder, and in progressing disease, is to cholestasis and this shown anticipate evaluating and in the study year, of our in is biliary for Xb of higher evaluates line with and sclerosing a Xb atresia liver acid pregnancy. year. dose believe greater as top OHANA in this intrahepatic cholangitis treatment Phase we the been in later expect excited We study evaluate primary second serum. Phase has MARCH-PFIC data is Earlier transformative As several cholestatic A volixibat Phase for primary launched are our targeted of
into We design studies, volixibat regulatory of potentially have incorporated all feedback are which these registrational. the of
On to off the access we Mirum’s studies our to OHANA into Cambridge for Both note, for of China, are launch and our to for approval an to analyses April. based Peter? occur testament And as patients. over to partners rare maralixibat the Peter, U.S. next I leaders readiness want recently in on Pharma discuss to GC readiness, ensuring an maralixibat facilitate the exclusive turn partnership it cholestasis to who builds filing announced see interim Peter to package. expect the broad with and Pharmaceuticals will will to potential year. Cambridge commitment maralixibat touch commercialize This VISTAS syndrome and expedited Pharma will launch activities. We for GC and before pathways We To passion for I of overview agreement in in Greater and handing our of Alagille level to interest international alagille which licensing disease with that patients. of syndrome pediatric we Korea. maralixibat, pursue on on maralixibat in develop medicines entered global our advance share life-changing reach we our high provide South
